Stock LSTA LISATA THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Lisata Therapeutics, Inc.

Equities

LSTA

US1280583022

Delayed Nasdaq
Other stock markets
 12:57:49 2024-06-12 pm EDT 		5-day change 1st Jan Change
3.426 USD -6.63% Intraday chart for Lisata Therapeutics, Inc. +9.65% +25.51%
May. 20 Sector Update: Health Care Stocks Softer Late Afternoon MT
May. 20 Lisata Therapeutics Receives European Medicines Agency Pediatric Waiver for Pancreatic Cancer Treatment MT

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Lisata Therapeutics to Participate in Upcoming June 2024 Industry and Investor Events
GL
Lisata Therapeutics Receives Paediatric Investigation Plan Waiver from the European Medicines Agency for Certepetide in Pancreatic Cancer
GL
Lisata Therapeutics gets 2024 off to a strong start as it prepares for crucial ASCEND trial results
AQ
Lisata Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
GL
Lisata Therapeutics to Participate in Upcoming May 2024 Industry and Investor Events
GL
Lisata Therapeutics to Participate in Upcoming May 2024 Industry and Investor Events
AQ
Lisata Therapeutics to Report First Quarter 2024 Financial Results and Provide a Business Update on Thursday, May 9, 2024
GL
Lisata Therapeutics to Report First Quarter 2024 Financial Results and Provide a Business Update on Thursday, May 9, 2024
AQ
Lisata Therapeutics and Qilu Pharmaceutical Announce First Patient Treated in Qilu's Phase 2 Trial in China of LSTA1 in Patients with Metastatic Pancreatic Ductal Adenocarcinoma
AQ
Lisata Therapeutics advances lead asset LSTA1 for treatment of advanced solid tumors
AQ
Lisata Therapeutics and Qilu Pharmaceutical Announce First Patient Treated in Qilu’s Phase 2 Trial in China of LSTA1 in Patients with Metastatic Pancreatic Ductal Adenocarcinoma
GL
Lisata Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to LSTA1 for the Treatment of Osteosarcoma
GL
Lisata Therapeutics to Participate in Upcoming April 2024 Industry and Investor Events
GL
Lisata Therapeutics Announces U.S. FDA Rare Pediatric Disease Designation Granted to LSTA1 for the Treatment of Osteosarcoma
GL
Lisata Therapeutics to Present at the Life Science Investor Forum on March 7ᵗʰ
AQ
Lisata Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update
GL
Lisata Therapeutics to Host Year-End 2023 Conference Call on Thursday, February 29, 2024 at 4:30 p.m. Eastern Time
GL
Lisata Therapeutics to Host Year-End 2023 Conference Call on Thursday, February 29, 2024 at 4:30 p.m. Eastern Time
AQ
Lisata Therapeutics to Present at BIO CEO & Investor Conference
GL
Lisata Therapeutics to Present at the Sequire Investor Summit in Puerto Rico
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. LSTA Stock
  4. News Lisata Therapeutics, Inc.
  5. Press Releases